journal
Journals Journal of Dermatological Trea...

Journal of Dermatological Treatment

https://read.qxmd.com/read/38317538/oral-abrocitinib-in-the-treatment-of-granuloma-annulare-a-case-report
#21
JOURNAL ARTICLE
Wenyan Liu, Weifeng Chen, Xin Tian, Yihui Yu, Junhui Zhu, Jingyao Liang, Xibao Zhang
Aim: To evaluate the therapeutic efficacy and safety of JAK inhibitor abrocitinib in patients with localized granuloma annulare (GA) and to review the available cases documented in English. Methods: We presented a patient who had a persistent, localized granuloma anulare (GA) for one year and did not respond to traditional therapies. This patient was treated with oral abrocitinib at a dosage of 150 mg daily. Results: After 6 weeks of treatment with abrocitinib, the patient exhibited notable symptom improvement with no new lesions...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38317525/real-world-biologic-treatment-patterns-and-healthcare-resource-utilization-in-psoriasis-patients-using-an-insurance-claims-database-in-japan
#22
JOURNAL ARTICLE
Celine Miyazaki, Junya Masuda, Mateo Delclaux Rodriguez-Rey, Marta Natalia Stelmaszuk, Jonatan Freilich, Phiona I-Ching Tsai, Hidehisa Saeki
BACKGROUND: With advent of newer treatments for psoriasis, real-world use of biologics in Japan is evolving. METHODS: This retrospective study utilized data from patients with ≥1 psoriasis-related biologic claims record between January 2016 and December 2020 in Japan to evaluate treatment patterns, healthcare resource utilization (HCRU), and associated costs. Data were analyzed using descriptive statistics. RESULTS: Of 1,614 eligible patients, 72...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38317519/the-impact-of-hormones-in-autoimmune-cutaneous-diseases
#23
REVIEW
Lais Lopes Almeida Gomes, Adrienne J Werth, Preethi Thomas, Victoria P Werth
INTRODUCTION: Dermatomyositis, systemic and cutaneous lupus erythematosus have a significantly higher prevalence in women than men, emphasizing the relevance of exploring the relationship between sex hormones and autoimmune skin diseases. This review analyzes the interplay between sex hormones and these two skin diseases. MATERIALS AND METHODS: We performed an extensive literature search using the PubMed database from July to August 2023. Search terms included 'contraceptives', 'pregnancy', 'hormone replacement', 'tamoxifen', and 'aromatase inhibitors'...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38305215/effectiveness-and-safety-of-deucravacitinib-treatment-for-moderate-to-severe-psoriasis-in-real-world-clinical-practice-in-japan
#24
JOURNAL ARTICLE
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
BACKGROUND: Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently approved for psoriasis. OBJECTIVES: We aimed to evaluate the real-world effectiveness and safety of deucravacitinib for psoriasis. METHODS: We analyzed 33 Japanese patients with psoriasis (23 with plaque psoriasis, eight with psoriatic arthritis, and two with erythrodermic psoriasis) from January 2023 to October 2023. All patients received deucravacitinib 6 mg daily until week 16...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38297496/predictive-factors-for-responders-to-upadacitinib-treatment-in-patients-with-atopic-dermatitis
#25
JOURNAL ARTICLE
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
BACKGROUND: Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice. OBJECTIVES: To identify predictive factors for responders to upadacitinib 15 mg or 30 mg, defined as achievers of investigator's global assessment (IGA) 0/1 with ≥ 2-point improvement from basal IGA. METHODS: A retrospective study was conducted from August 2021 to July 2023 on 159 AD patients treated with upadacitinib 15 mg and 52 patients with 30 mg...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38297490/ruxolitinib-cream-monotherapy-demonstrates-rapid-improvement-in-the-extent-and-signs-of-mild-to-moderate-atopic-dermatitis-across-head-and-neck-and-other-anatomic-regions-in-adolescents-and-adults-pooled-results-from-2-phase-3-studies
#26
JOURNAL ARTICLE
Eric L Simpson, Robert Bissonnette, Zelma C Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F Stein Gold
Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents with mild to moderate AD were randomized to apply twice-daily ruxolitinib cream or vehicle for eight weeks. Here, we evaluated the efficacy and tolerability of ruxolitinib cream by anatomic region, focusing on head/neck (HN) lesions that are typically difficult to manage and disproportionately affect quality of life (QoL)...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38297481/leptin-induces-altered-differentiation-of-keratinocytes-by-inducing-insulin-resistance-implications-for-metabolic-syndrome-induced-resistance-of-psoriatic-therapy
#27
REVIEW
Rui Wang, Chongli Yu, Zijie Tang, Jie Sun, Youlin Wang, Zhenkai Zhao, Biwen Lin, Chengxin Li
Background: Psoriatic patients tend to develop metabolic syndrome (MS). MS accelerates psoriasis, but the exact molecular mechanisms are poorly understood. Objectives: We aim to investigate the impact of leptin on keratinocyte insulin sensitivity and explore its underlying molecular mechanism, which might play a role in the pathogenesis of this disease. Methods: ELISA and immunohistochemistry were applied respectively to detect the level of leptin in serum and in lesion of psoriatic patients with and without MS...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38297480/patients-preferences-for-systemic-treatment-of-atopic-dermatitis-safety-and-efficacy-count-the-most
#28
JOURNAL ARTICLE
Marthe-Lisa Schaarschmidt, Daniel Kromer, Phoebe Wellmann, Wiebke K Peitsch, Christian Kromer
BACKGROUND: The advent of biologics and janus kinase inhibitors has revolutionized treatment of atopic dermatitis (AD). OBJECTIVE: To investigate preferences of patients with AD for attributes of currently approved systemic treatments and assess influencing factors. METHODS: An online discrete choice experiment was conducted in patients with AD throughout Germany to analyze preferences for outcome (probability of (almost) clear skin at week 16, probability of significant itch improvement, time to onset of itch relief and type of side effects) and process attributes (application method and frequency of laboratory tests)...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38291602/expression-of-mast-cell-tryptase-and-immunoglobulin-e-is-increased-in-cutaneous-photodamage-implications-for-carcinogenesis
#29
JOURNAL ARTICLE
Jenni Korhonen, Hanna Siiskonen, Salla Haimakainen, Rauno J Harvima, Ilkka T Harvima
Purpose: Mast cells, their serine proteinase tryptase, and immunoglobulin E (IgE) can be involved in cutaneous carcinogenesis. Materials and methods: To study the association of tryptase+ and IgE+ cells with photodamage and skin cancers 385 adult patients (201 males, 184 females, 75 with immunosuppression) at risk of any type of skin cancer were examined. Skin biopsies were taken from the sun-protected medial arm and from the photodamaged dorsal forearm skin followed by immunohistochemical staining for tryptase and IgE...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38263716/impairment-in-work-and-activities-of-daily-life-in-patients-with-psoriasis-results-of-the-prospective-biocapture-registry
#30
JOURNAL ARTICLE
Tamara W van Hal, Juul M P A van den Reek, Mark H Wenink, Marisol E Otero, Paul M Ossenkoppele, Marcellus D Njoo, Annet Oostveen, Bas Peters, Milan Tjioe, Else N Kop, John E M Körver, Sharon R P Dodemont, Marloes M Kleinpenning, Maartje A M Berends, Wendelien R Veldkamp, Martijn B A van Doorn, Johannes M Mommers, Robert-Jan Lindhout, Astrid L A Kuijpers, Paula P van Lümig, C Els J de Jonge, Ron A Tupker, Judith Hendricksen, Romy R Keijsers, Frank H J van den Hoogen, Johanna E Vriezekolk, Elke M G J de Jong
Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38263709/the-expression-of-cd200-and-cd23-on-b-lymphocytes-in-the-pollen-season-and-outside-the-pollen-season-in-atopic-dermatitis-patients-with-and-without-dupilumab-therapy
#31
JOURNAL ARTICLE
Jarmila Čelakovská, Eva Čermáková, Ctirad Andrýs, Petra Boudkova, Jan Krejsek
No abstract text is available yet for this article.
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38263708/upadacitinib-for-the-management-of-bullous-pemphigoid-coexisting-with-psoriasis-vulgaris-a-case-report-and-literature-review
#32
JOURNAL ARTICLE
Fangying Su, Tai Wang, Qunshi Qin, Zhi Xie
Both bullous pemphigoid (BP) and psoriasis are common immune-related dermatological conditions in clinical practice, but the co-occurrence of these two diseases is rare. Currently, there is no consensus on the long-term safe and effective treatment for patients with both BP and psoriasis. JAK inhibitors are emerging as targeted therapeutic drugs that act by inhibiting Janus kinase activity, regulating the JAK/STAT pathway, blocking the transduction pathway of key proinflammatory cytokines, and influencing T-cell differentiation...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38258513/a-therapeutic-challenge-managing-severe-atopic-dermatitis-with-concurrent-alpha-1-antitrypsin-deficiency
#33
JOURNAL ARTICLE
M Cebolla-Verdugo, C Llamas-Segura, L Linares-González, R Ruiz-Villaverde, F J Navarro-Triviño
No abstract text is available yet for this article.
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38247364/the-efficacy-and-safety-of-low-dose-rituximab-in-the-treatment-of-pemphigus-vulgaris-a-cohort-study
#34
JOURNAL ARTICLE
Xingli Zhou, Tongying Zhan, Xiaoxi Xu, Tianjiao Lan, Hongxiang Hu, Yuxi Zhou, Dengmei Xia, Jinqiu Wang, Yiyi Wang, Yue Xiao, Wei Li
BACKGROUND: Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on the optimum dosage has been achieved. OBJECTIVES: To investigate the efficacy and safety of low-dose RTX (a single infusion of 500 mg) for the treatment of PV, a cohort study was conducted for patients with PV, along with a 12-month follow-up following the administration of RTX. METHODS: Patients with moderate or severe PV were divided into group A (low-dose RTX combined with corticosteroids) and group B (corticosteroids alone)...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38240290/correction
#35
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38240111/injection-site-reactions-after-dupilumab-or-tralokinumab-for-atopic-dermatitis
#36
JOURNAL ARTICLE
Fabrizio Martora, Cataldo Patruno, Silvia D'Ascenzo, Maddalena Napolitano
Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection. Objective: ISR is reported as a frequent adverse event after subcutaneous injection (SCI) of several biologics. Methods: We performed an observational real-life study to compare dupilumab and tralokinumab as regards ISR, analysing frequency, duration and intensity of symptoms related to SCI. From January 2023 to June 2023, we enrolled adult patients affected by moderate to severe AD and being on dupilumab or tralokinumab treatment...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38240097/complete-response-of-extensive-alopecia-areata-refractory-to-baricitinib-after-five-months-of-treatment-with-upadacitinib
#37
JOURNAL ARTICLE
Francisco Javier De la Torre-Gomar, Juan Pablo Velasco-Amador, Álvaro Prados-Carmona, Ricardo Ruiz-Villaverde
No abstract text is available yet for this article.
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38240095/monitoring-adherence-to-vulvar-lichen-sclerosus-treatment-a-prospective-study
#38
JOURNAL ARTICLE
Mallory L Zaino, Jessica N Pixley, Vani Mangalam Subramanian, Deepak Sirdeshmukh, Steven R Feldman, Rita O Pichardo
Background: Vulvar lichen sclerosus treatment consists of topical corticosteroids followed by maintenance therapy. Self-reported adherence to topical corticosteroids in vulvar lichen sclerosus is approximately 66-70.4% and adherence to chronic topical medications is poor. Objective: To measure treatment adherence for vulvar lichen sclerosus. Methods: Adults with vulvar lichen sclerosus who were receiving or who were candidates to receive treatment with topical clobetasol propionate 0.05% ointment twice daily received medication tubes equipped with adherence monitors capturing the time and amount of dose dispensed...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38230424/comparison-of-various-excimer-laser-el-combination-therapies-for-vitiligo-a-systematic-review-and-network-meta-analysis
#39
REVIEW
ChanXiu Li, Yue Hu, ZengYi Mu, Lei Shi, Xiao Sun, XinYue Wang, YaPing Wang, XinHong Li
AIM: This study aimed to compare the efficacy and safety of excimer laser (EL)-based combination regimens in improving repigmentation. METHODS: A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, and Embase on July 1, 2023, to include randomized controlled trials of EL combination treatments for vitiligo that met the criteria. The primary outcome measure was a repigmentation rate ≥ 75%, and the secondary outcome measures were a repigmentation rate of ≤ 25% and adverse events...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38230420/is-apremilast-a-treatment-for-sapho-syndrome
#40
JOURNAL ARTICLE
Ju Zhang, Yixuan Li, Jing Wang, Huan Jiang, Jiaping Qi, Chen Li, Zhenhua Ying
No abstract text is available yet for this article.
December 2024: Journal of Dermatological Treatment
journal
journal
30315
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.